Li, Ting
Guo, Jiang
Liu, Yushen
Du, Zhaoqing
Guo, Zhaoyang
Fan, Yangwei
Cheng, Long
Zhang, Yue
Gao, Xu
Zhao, Yunyu
He, Xinyuan
Wu, Wenhua
Gao, Ning
Wu, Yinying
Li, Jie
Zhang, Yu
Kang, Wen
Cai, Zhifang
Wang, Wenjun
Li, Xiaopeng
Zan, Ying
Nguyen, Mindie H. http://orcid.org/0000-0002-6275-4989
Ji, Fanpu http://orcid.org/0000-0002-1463-8035
Funding for this research was provided by:
Natural Science Foundation of Shaanxi Province (No.2022SF-451, No.2022SF-451)
National Natural Science Foundation of China (No.82170626)
Article History
Received: 13 June 2022
Accepted: 9 February 2023
First Online: 25 February 2023
Declarations
:
: Author’s declaration of personal interests: Mindie H. Nguyen: Grants: Gilead, Pfizer, Enanta, Vir, Glycotest, National Cancer Institute, B. K. Kee Foundation, Exact Sciences; Helio Health; Consulting or advisory board: Intercept, Gilead, Exact Sciences, Laboratory of Advanced Medicine, Bayer, Eisai, GSK, Novartis. Fanpu Ji: Speaker: Gilead Sciences, MSD and Ascletis. Consulting or advisory board: Gilead Sciences and MSD. All other authors do not have conflict of interest.
: This study was carried out in accordance with the International Conference on Good Clinical Practice Standards and the Declaration of Helsinki and was approved by the Institutional Ethics Committees of The Second Affiliated Hospital of Xi’an Jiaotong University (2018059; Shaanxi, China). Institutional ethics review was waived at other participating centers.
: Informed consent was obtained from all participants included in the study.
: All data and materials of this study are available from the corresponding author upon request.